2017
Neratinib shows efficacy in the treatment of HER2/neu amplified epithelial ovarian carcinoma in vitro and in vivo
Menderes G, Bonazzoli E, Bellone S, Black J, Pettinella F, Masserdotti A, Zammataro L, Lopez S, Litkouhi B, Ratner E, Silasi D, Azodi M, Schwartz P, Santin A. Neratinib shows efficacy in the treatment of HER2/neu amplified epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology 2017, 145: 112. DOI: 10.1016/j.ygyno.2017.03.263.Peer-Reviewed Original Research
2009
Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent/Chemotherapy-Resistant Epithelial Ovarian Cancer: Implications for Epithelial Cell Adhesion Molecule-Specific Immunotherapy
Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent/Chemotherapy-Resistant Epithelial Ovarian Cancer: Implications for Epithelial Cell Adhesion Molecule-Specific Immunotherapy. International Journal Of Gynecological Cancer 2009, 19: 860-866. PMID: 19574774, DOI: 10.1111/igc.0b013e3181a8331f.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdenocarcinoma, MucinousAdultAntigens, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsBlotting, WesternCarcinoma, PapillaryCell Adhesion MoleculesChemotherapy, AdjuvantCystadenocarcinoma, SerousDrug Resistance, NeoplasmEndometrial NeoplasmsEpithelial Cell Adhesion MoleculeFemaleFlow CytometryHumansImmunoenzyme TechniquesMiddle AgedNeoplasm Recurrence, LocalOrganoplatinum CompoundsOvarian NeoplasmsOvaryPrognosisRetrospective StudiesReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSurvival RateTreatment OutcomeTumor Cells, CulturedConceptsRecurrent epithelial ovarian carcinomaEpithelial ovarian carcinomaNormal ovarian tissuesOvarian carcinoma cell linesOvarian carcinomaEpithelial cell adhesion moleculeEp-CAMCarcinoma cell linesCell adhesion moleculeOvarian tissueChemotherapy-resistant epithelial ovarian cancerFlow cytometryCell linesAdhesion moleculesEp-CAM overexpressionStandard treatment modalityCell adhesion molecule expressionOvarian carcinoma patientsEpithelial ovarian cancerPrimary ovarian carcinomasAdhesion molecule expressionSurface expressionAntibody-mediated therapyHuman monoclonal antibodyEpithelial cell adhesion molecule (EpCAM) expression
2008
Corrigendum to “Immunogenic gangliosides in human ovarian carcinoma” [Biochem. Biophys. Res. Commun. 353 (2007) 251–258]
Ravindranath M, Muthugounder S, Presser N, Selvan S, Santin A, Bellone S, Saravanan T, Morton D. Corrigendum to “Immunogenic gangliosides in human ovarian carcinoma” [Biochem. Biophys. Res. Commun. 353 (2007) 251–258]. Biochemical And Biophysical Research Communications 2008, 377: 1331. DOI: 10.1016/j.bbrc.2008.09.103.Peer-Reviewed Original Research